Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Treatment for chronic myelogenous leukemia: the long road to imatinib.

Hunter T.

J Clin Invest. 2007 Aug;117(8):2036-43. Review.

2.

Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates.

An DS, Donahue RE, Kamata M, Poon B, Metzger M, Mao SH, Bonifacino A, Krouse AE, Darlix JL, Baltimore D, Qin FX, Chen IS.

Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13110-5. Epub 2007 Aug 1.

3.

Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia.

Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH.

Clin Exp Med. 2007 Jun;7(2):47-55. Epub 2007 Jul 4.

PMID:
17609876
4.

RNAi therapeutics: principles, prospects and challenges.

Aagaard L, Rossi JJ.

Adv Drug Deliv Rev. 2007 Mar 30;59(2-3):75-86. Epub 2007 Mar 16. Review.

5.

Production and purification of lentiviral vectors.

Tiscornia G, Singer O, Verma IM.

Nat Protoc. 2006;1(1):241-5.

PMID:
17406239
6.

Design and cloning of lentiviral vectors expressing small interfering RNAs.

Tiscornia G, Singer O, Verma IM.

Nat Protoc. 2006;1(1):234-40.

PMID:
17406238
7.

Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.

Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME.

Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5715-21. Epub 2007 Mar 22.

8.

Strategies for silencing human disease using RNA interference.

Kim DH, Rossi JJ.

Nat Rev Genet. 2007 Mar;8(3):173-84. Review.

PMID:
17304245
10.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators.

N Engl J Med. 2006 Dec 7;355(23):2408-17.

11.

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.

Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ.

Blood. 2007 Jan 15;109(2):500-2. Epub 2006 Sep 21.

12.

MicroRNAs: expression, avoidance and subversion by vertebrate viruses.

Sarnow P, Jopling CL, Norman KL, Schütz S, Wehner KA.

Nat Rev Microbiol. 2006 Sep;4(9):651-9. Review.

PMID:
16912711
13.

Treating imatinib-resistant leukemia: the next generation targeted therapies.

Burgess MR, Sawyers CL.

ScientificWorldJournal. 2006 Aug 11;6:918-30.

14.

Targeting lentiviral vectors to specific cell types in vivo.

Yang L, Bailey L, Baltimore D, Wang P.

Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11479-84. Epub 2006 Jul 24.

15.

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T.

Nat Med. 2006 Aug;12(8):908-16. Epub 2006 Jul 23.

16.

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL.

N Engl J Med. 2006 Jun 15;354(24):2531-41.

17.

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.

Azam M, Nardi V, Shakespeare WC, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, Daley GQ.

Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9244-9. Epub 2006 Jun 5.

18.

Targeting leukemic fusion proteins with small interfering RNAs: recent advances and therapeutic potentials.

Thomas M, Greil J, Heidenreich O.

Acta Pharmacol Sin. 2006 Mar;27(3):273-81. Review.

20.

Second-generation shRNA libraries covering the mouse and human genomes.

Silva JM, Li MZ, Chang K, Ge W, Golding MC, Rickles RJ, Siolas D, Hu G, Paddison PJ, Schlabach MR, Sheth N, Bradshaw J, Burchard J, Kulkarni A, Cavet G, Sachidanandam R, McCombie WR, Cleary MA, Elledge SJ, Hannon GJ.

Nat Genet. 2005 Nov;37(11):1281-8. Epub 2005 Oct 2.

PMID:
16200065

Supplemental Content

Support Center